Download or read book Tuberculosis Treatment The Search For New Drugs written by Marcus V.N. de Souza and published by Bentham Science Publishers. This book was released on 2013-11-21 with total page 236 pages. Available in PDF, EPUB and Kindle. Book excerpt: Despite the high impact on human health caused by Tuberculosis (TB) infections worldwide, nearly 45 years have passed since a novel drug was introduced for its treatment. As MDR-TB and XDR-TB cases rise globally new strategies and drugs are desperately needed to address this problem. Tuberculosis Treatment: The Search For New Drugs covers a wide range of topics about TB drug discovery. The e-book begins with historical information about Tuberculosis discovery and treatment and explores modern treatment strategies, formulations (synthetic and natural) and class of compounds. The extraction of important drugs from various sources is also covered in separate chapters along with information about promising drugs undergoing clinical testing. The e-book is a useful reference for readers interested in learning about the array of pharmaceuticals discovered and used to combat Mycobacterium tuberculosis infections.

Download or read book Tuberculosis Treatment The Search for New Drugs written by Megan Durham and published by Hayle Medical. This book was released on 2023-09-26 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tuberculosis (TB) refers to a type of infectious disease generally caused by Mycobacterium tuberculosis. Lungs are the primary target of this disease, but it can also affect the other parts of the body. It can be treated with a combination of antibacterial medications. However, the evolution of drug-resistant tuberculosis necessitates the development of effective, novel and safe drug regimens. Drug discovery and development is a difficult, expensive and time-consuming process. One of the popular frameworks used in drug discovery is model-informed drug discovery and development (MID3). It aims to provide an informative prediction of drug efficacy and exposure in people for choosing innovative anti-tuberculosis drug combinations. This book is compiled in such a manner, that it will provide in-depth knowledge about drug discovery for treating tuberculosis. Those with an interest in this area of pharmaceutical science would find it helpful.

Download or read book Treatment of Tuberculosis written by World Health Organization and published by . This book was released on 1993 with total page 60 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Disease Control Priorities Third Edition Volume 6 written by King K. Holmes and published by World Bank Publications. This book was released on 2017-11-06 with total page 506 pages. Available in PDF, EPUB and Kindle. Book excerpt: Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

Download or read book Tuberculosis Drug Discovery and Development 2019 written by Giovanna Riccardi and published by MDPI. This book was released on 2020-11-24 with total page 296 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main causes of death due to a single pathogen. Standard anti-TB therapy includes four first-line antibiotics that should be administered for at least six months. However, in the case of multi- and extensively drug-resistant TB, second-line medications must be used and these frequently cause severe side effects resulting in poor compliance. Developing new anti-TB drug candidates is therefore of outmost importance. In this Special Issue dedicated to Tuberculosis Drug Discovery and Development, we present the main and latest achievements in the fields of drug and target discovery, host-directed therapy, anti-virulence drugs, and describe the development of two advanced compounds: macozinone and delpazolid. In addition, this Special Issue provides an historical perspective focused on Carlo Forlanini, the inventor of pneumothorax for TB treatment, and includes an overview of the state-of-the-art technologies which are being exploited nowadays in TB drug development. Finally, a summary of TB vaccines that are either approved or undergoing clinical trials concludes the Special Issue.

Download or read book The New Profile of Drug Resistant Tuberculosis in Russia written by Russian Academy of Medical Sciences and published by National Academies Press. This book was released on 2011-07-07 with total page 158 pages. Available in PDF, EPUB and Kindle. Book excerpt: An estimated 2 billion people, one third of the global population, are infected with Mycobacterium tuberculosis, the bacterium that causes tuberculosis. Spread through the air, this infectious disease killed 1.7 million in 2009, and is the leading killer of people with HIV. Tuberculosis (TB) is also a disease of poverty-the vast majority of tuberculosis deaths occur in the developing world. Exacerbating the devastation caused by TB is the growing threat of drug-resistant forms of the disease in many parts of the world. Drug-resistant tuberculosis presents a number of significant challenges in terms of controlling its spread, diagnosing patients quickly and accurately, and using drugs to treat patients effectively. In Russia in recent decades, the rise of these strains of TB, resistant to standard antibiotic treatment, has been exacerbated by the occurrence of social, political, and economic upheavals. The Institute of Medicine (IOM) Forum on Drug Discovery, Development, and Translation, in conjunction with the Russian Academy of Medical Sciences held a workshop to discuss ways to fight the growing threat of drug-resistant TB. The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop presents information from experts on the nature of this threat and how it can be addressed by exploring various treatment and diagnostic options.

Download or read book WHO consolidated guidelines on tuberculosis Module 4 written by World Health Organization and published by World Health Organization. This book was released on 2022-04-30 with total page 72 pages. Available in PDF, EPUB and Kindle. Book excerpt: Between 2011 and 2019, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO Consolidated Guidelines on Drug Resistant Tuberculosis Treatment, issued by WHO in March 2019. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development Groups, using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to summarize the evidence, and formulate policy recommendations and accompanying remarks. The present WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment includes a comprehensive set of WHO recommendations for the treatment and care of DR-TB. The document includes two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and MDR/RR-TB, including longer regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), the use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care. The guidelines are to be used primarily in national TB programmes, or their equivalents in Ministries of Health, and for other policy-makers and technical organizations working on TB and infectious diseases in public and private sectors and in the community.

Download or read book Guidelines for the Programmatic Management of Drug Resistant Tuberculosis written by World Health Organization and published by . This book was released on 2015-04-20 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response to the Sixty-second World Health Assembly's resolution on prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Resolution WHA62.15, adopted in 2009, calls on Member States to develop a comprehensive framework for the management and care of patients with drug-resistant TB. The recommendations contained in these guidelines address the most topical questions concerning the programmatic management of drug-resistant TB: case-finding, multidrug resistance, treatment regimens, monitoring the response to treatment, and selecting models of care. The guidelines primarily target staff and medical practitioners working in TB treatment and control, and partners and organizations providing technical and financial support for care of drug-resistant TB in settings where resources are limited.

Download or read book Nanotechnology Based Approaches for Tuberculosis Treatment written by Prashant Kesharwani and published by Academic Press. This book was released on 2020-06-10 with total page 284 pages. Available in PDF, EPUB and Kindle. Book excerpt: Nanotechnology Based Approaches for Tuberculosis Treatment discusses multiple nanotechnology-based approaches that may help overcome persisting limitations of conventional and traditional treatments. The book summarizes the types of nano drugs, their synthesis, formulation, characterization and applications, along with the most important administration routes. It also explores recent advances and achievements regarding therapeutic efficacy and provides possible future applications in this field. It will be a useful resource for investigators, pharmaceutical researchers, innovators and scientists working on technology advancements in the areas of targeted therapies, nano scale imaging systems, and diagnostic modalities in tuberculosis. Addresses the gap between nanomedicine late discovery and early development of tuberculosis therapeutics Explores tuberculosis nanomedicine standardization and characterization with newly developed treatment, diagnostic and treatment monitoring modalities Covers the field thoroughly, from the pathogenesis of tuberculosis and multi-drug resistant mycobacterium tuberculosis, to treatment approaches using nanotechnology and different nanocarriers

Download or read book Tuberculosis in Adults and Children written by Dorothee Heemskerk and published by Springer. This book was released on 2015-07-17 with total page 66 pages. Available in PDF, EPUB and Kindle. Book excerpt: This work contains updated and clinically relevant information about tuberculosis. It is aimed at providing a succinct overview of history and disease epidemiology, clinical presentation and the most recent scientific developments in the field of tuberculosis research, with an emphasis on diagnosis and treatment. It may serve as a practical resource for students, clinicians and researchers who work in the field of infectious diseases.

Download or read book Ethics and Drug Resistance Collective Responsibility for Global Public Health written by Euzebiusz Jamrozik and published by Springer. This book was released on 2021-08-21 with total page 448 pages. Available in PDF, EPUB and Kindle. Book excerpt: This Open Access volume provides in-depth analysis of the wide range of ethical issues associated with drug-resistant infectious diseases. Antimicrobial resistance (AMR) is widely recognized to be one of the greatest threats to global public health in coming decades; and it has thus become a major topic of discussion among leading bioethicists and scholars from related disciplines including economics, epidemiology, law, and political theory. Topics covered in this volume include responsible use of antimicrobials; control of multi-resistant hospital-acquired infections; privacy and data collection; antibiotic use in childhood and at the end of life; agricultural and veterinary sources of resistance; resistant HIV, tuberculosis, and malaria; mandatory treatment; and trade-offs between current and future generations. As the first book focused on ethical issues associated with drug resistance, it makes a timely contribution to debates regarding practice and policy that are of crucial importance to global public health in the 21st century.

Download or read book Development of New Antituberculosis Drugs written by W. W. Yew and published by Nova Publishers. This book was released on 2006 with total page 328 pages. Available in PDF, EPUB and Kindle. Book excerpt: In the global war to control tuberculosis (TB), there are several critical battles which must be waged and won if we are to make significant progress. Broadly speaking, these battlefields may be regarded as diagnosis, treatment and prevention. Within the arena of treatment are various critical elements. Current drug regimens require 6 months to achieve predictable cures; it is essential that shorter regimens be developed to lessen non-adherence and to improve affordability. To facilitate directly-observed therapy, intermittent (less than daily) regimens have been employed. To ensure favourable outcomes, including patients with AIDS, thrice-weekly regimens are the current standard; reducing the frequency of dosing to twice- or once-weekly may offer significant advantages. Drug resistance to the current major medications, the rifamycins and isoniazid, threatens to make tuberculosis untreatable for rising numbers of patients in many regions of the world. Finding new, effective agents is essential to ensure cures for these cases and to halt transmission of multidrug-resistant tuberculosis to others. Additional issues include reducing the side effects and toxicity of anti-tuberculosis regimens and developing regimens that can be given simultaneously with anti-retroviral therapy without deleterious drug-drug interactions or unacceptable toxicity. Finally, attention must be directed to the potential utility of treating latent infection to prevent the evolution of active disease. The current vaccine Bacille Calmette-Guerin (BCG), while protecting infants and children against potentially lethal forms of TB, has done little to control the incidence of communicable adult pulmonary disease. Research is underway to develop improved vaccines, but due to the prolonged period to determine the efficacy of a TB vaccine (a minimum of 10 to 20 years) -- alternative strategies must be pursued. Furthermore, the utility of a traditional vaccine would be sorely limited by the fact that roughly two billion persons today harbour latent tuberculosis infection. This huge reservoir of future disease would not be eligible for a traditional pre-infection vaccine. "Preventive therapy" with isoniazid has been shown to reduce the subsequent risk of tuberculosis by about 70% in large, randomised placebo-controlled clinical trials. However, this strategy is limited by the requirement for extended duration of treatment (6 to 9 months), the risks of drug-induced hepatitis and rising rates of resistance to isoniazid in many regions of the world where the TB epidemic is most intense. Alternative means for the treatment of latent tuberculosis infection should be given high priority. The authors have assembled an outstanding panel of contributors to address these issues. The topics herein have great relevance both in the industrialised nations where contemporary medications and strategies appear to have exacted their maximum benefits and for the developing nations where this ancient scourge remains rampant. This book will provide an impetus for authorities and organisations devoted to the development of new drugs to address the aforementioned growing problems of TB world-wide.

Download or read book HIV related TB written by and published by . This book was released on 1993 with total page 20 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Timebomb The Global Epidemic of Multi Drug Resistant Tuberculosis written by Lee Reichman and published by McGraw Hill Professional. This book was released on 2001-11-05 with total page 258 pages. Available in PDF, EPUB and Kindle. Book excerpt: "This is an excellent book. It should be read by all who are interested in any aspect of Tuberculosis, including the growing problem of Multi-Drug Resistant Tuberculosis." Journal of American Medical Association "The book serves an important function, relaying statistics and TB hot spots, proposing funding and international standardized treatments. Government officials, researchers and nonprofit health organizations will likely cast this as the authoritative book on the subject." Publishers Weekly "Like other recent works on the threat of infectious diseases such as Laurie Garrett's The Coming Plague, Timebomb has the power of fiction and it is sometimes easy to forget that it is not. Unlike the Garrett book, which is more a collection of short dramatic stories collectively telling a big picture about our coexistence and evolution with microbes, Reichman selects one story and presents it in novel form with better material that most science fiction. The book is organized in a clear and riveting manner. Within the narrative style, the book is rich with up-to-the-minute details and references that add to its depth. An incredible account of politics and disease dynamics occurring at all levels, Timebomb helps us realize that controlling or eradicating TB is not just about science and facts; likely if it were, TB would have long been relegated to the history books." Nature Medicine Magazine Tuberculosis, supposedly defeated by antibiotics half a century ago, has returned in a highly contagious and fatal new form that cannot be treated with conventional drugs. Multidrug-resistant TB (MDR-TB), could cause some 10 million deaths over the next decade and is thriving in the overcrowded prisons of the former Soviet Union. As Timebomb explains in unnerving detail, the virtual collapse of the world's borders means that refugees, tourists, immigrants, business travelers, and others can spread the TB bacillus very efficiently. London, for example, has experienced a 100% increase in reported cases in the past 10 years. Written by the world's preeminent TB expert and an award-winning medical and health writer, Timebomb details the evolution and the current state of the MDR-TB epidemic, interweaving the science of MDR-TB with personal stories of people whose lives have been threatened by the deadly bacteria.

Download or read book Tuberculosis in Clinical Practice written by Onn Min Kon and published by Springer Nature. This book was released on 2021-10-27 with total page 378 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is targeted at ensuring frontline clinical staff including seniors, trainees and specialist nurses can easily reference the optimum investigation and management of potential TB cases. This will mirror the annual London Advanced TB course which aims to equip all of the team delivering care to have a working knowledge of the entire spectrum of the real life aspects of TB management ranging from investigation of active TB to latent screening in pre biologic therapy. It includes an update of MDR TB management and also the approaches needed to ensure the entire medico-social spectrum of TB care is addressed.

Download or read book Handbook of Global Tuberculosis Control written by Yichen Lu and published by Springer. This book was released on 2017-06-09 with total page 558 pages. Available in PDF, EPUB and Kindle. Book excerpt: This ambitious reference surveys worldwide efforts at controlling the spread of tuberculosis, with special emphasis on the developing world. Case studies from China, Pakistan, Nigeria, Indonesia, and other frontline countries demonstrate a wealth of information on clinical, cultural, socioeconomic, and other relevant factors. This compilation provides a valuable resource for creating successful intervention and prevention strategies. State-of-the-science snapshots pinpoint where short- and long-term initiatives stand today, from early detection and vaccination programs to new genetic technologies and drug therapies. This diverse group of perspectives and approaches offers innovative paths toward control and realistic odds for containing the threat, especially in the face of current co-epidemics and new drug-resistant strains. Among the topics in the Handbook: Diagnosis of tuberculosis: current pipeline, unmet needs, and new developments Concurrence of tuberculosis and other major diseases The tuberculosis outbreak response, investigation, and control The promise of new TB vaccines DNA fingerprinting of Mycobacterium tuberculosis: a rich source of fundamental and daily applicable knowledge Global tuberculosis surveillance The Handbook of Global Tuberculosis Control is urgent reading for leadership and staff of non-governmental organizations, government agencies, academic institutions, research centers, hospitals, and potentially businesses with interests in tuberculosis control. Additionally, the book's focus on TB in developing countries will attract a wider audience of practitioners, particularly those working in the broader fields of global public health, epidemiology, international development, and the socioeconomics of infectious diseases.

Download or read book Guidelines on the Management of Latent Tuberculosis Infection written by World Health Organization and published by World Health Organization. This book was released on 2015-01-15 with total page 38 pages. Available in PDF, EPUB and Kindle. Book excerpt: BACKGROUND: Latent tuberculosis infection (LTBI), defined as a state of persistent immune response to prior-acquired Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB, affects about one-third of the world's population. Approximately 10% of people with LTBI will develop active TB disease in their lifetime, with the majority developing it within the first five years after initial infection. Currently available treatments have an efficacy ranging from 60% to 90%. Systematic testing and treatment of LTBI in at-risk populations is a critical component of WHO's eight-point framework adapted from the End TB Strategy to target pre-elimination and, ultimately, elimination in low incidence countries. OVERVIEW: Recognizing the importance of expanding the response to LTBI, in 2014 WHO developed Guidelines on the Management of Latent Tuberculosis Infection. The guidelines are primarily targeted at high-income or upper middle-income countries with an estimated TB incidence rate of less than 100 per 100 000 population, because they are most likely to benefit from it due to their current TB epidemiology and resource availability. The overall objective of the guidelines is to provide public health approach guidance on evidence-based practices for testing, treating and managing LTBI in individuals with the highest risk of progression to active disease. Specific objectives include identifying and prioritizing at-risk population groups for targeted intervention of LTBI testing and treatment, including defining an algorithm, and recommending specific treatment options. The guidelines are expected to provide the basis and rationale for the development of national guidelines for LTBI management based on available resources, epidemiology of TB including intensity of transmission, the health-care delivery system of the country, and other national and local determinants.